Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2015

Open Access 01-12-2015 | Research article

Validation of potential candidate biomarkers of drug-induced nephrotoxicity and allodynia in medication-overuse headache

Authors: Elisa Bellei, Emanuela Monari, Stefania Bergamini, Aurora Cuoghi, Aldo Tomasi, Simona Guerzoni, Michela Ciccarese, Luigi Alberto Pini

Published in: The Journal of Headache and Pain | Issue 1/2015

Login to get access

Abstract

Background

Medication-overuse headache (MOH) is a chronic disorder that results from the overuse of analgesics drugs, triptans or other acute headache compounds. Although the exact mechanisms underlying MOH remain still unknown, several studies suggest that it may be associated with development of “central sensitization”, which may cause cutaneous allodynia (CA). Furthermore, the epidemiology of drug-induced disorders suggests that medication overuse could lead to nephrotoxicity. The aim of this work was to confirm and validate the results obtained from previous proteomics studies, in which we analyzed the urinary proteome of MOH patients in comparison with healthy non-abusers individuals.

Methods

MOH patients were divided into groups on the basis of the drug abused: triptans, non-steroidal anti-inflammatory drugs (NSAIDs) and mixtures, (mainly containing indomethacin, paracetamol and, in some cases, caffeine). Healthy subjects, with a history of normal renal function, were used as controls. In this study, four proteins that were found differentially expressed in urine, and, on the basis of the literature review, resulted related to kidney diseases, were verified by Western Blot and Enzyme-linked Immunosorbent Assay (ELISA); Prostaglandin-H2 D-synthase (PTGDS), uromodulin (UROM), alpha-1-microglobulin (AMBP) and cystatin-C (CYSC).

Results

Western blot analysis allowed to validate our previous proteomics data, confirming that all MOH patients groups show a significant over-excretion of urinary PTGDS, UROM, AMBP and CYSC (excluding triptans group for this latter), in comparison with controls. Moreover, the expression of PTGDS was further evaluated by ELISA. Also by this assay, a significant increase of PTGDS was observed in all MOH abusers, according to 2-DE and Western blot results.

Conclusions

In this study, we confirmed previous findings concerning urinary proteins alterations in MOH patients, identified and demonstrated the over-expression of PTGDS, UROM, AMBP, and CYSC, particularly in NSAIDs and mixtures abusers. Over-expression of these proteins have been related to renal dysfunction and probably, PTGDS, to the development of CA. The detection and confirmation of this proteins pattern represent a promising tool for a better understanding of potential nephrotoxicity induced by drugs overuse and may enhance awareness related to the MOH-associated risks, even in absence of clinical symptoms.

Literature
  1. Negro A, Martelletti P (2011) Chronic migraine plus medication overuse headache: two entities or not? J Headache Pain 12:593–601PubMed CentralView ArticlePubMed
  2. Evers S, Marziniak M (2010) Clinical features, pathophysiology, and treatment of medication-overuse headache. Lancet Neurol 9:391–401View ArticlePubMed
  3. Dodick D, Silberstein S (2006) Central sensitization theory of migraine: clinical implications. Headache 46(Suppl 4):S82–S91
  4. De Felice M, Ossipov MH, Porreca F (2011) Persistent medication-induced neural adaptations, descending facilitation, and medication overuse headache. Curr Opin Neurol 24:193–196View ArticlePubMed
  5. Bigal ME, Ashina S, Burstein R, Reed ML, Buse D, Serrano D, Lipton RB (2008) Prevalence and characteristics of allodynia in headache suffers: a population study. Neurology 70(17):1525–1533PubMed CentralView ArticlePubMed
  6. Lipton RB, Bigal ME, Ashina S, Burstein R, Silberstein S, Reed ML, Serrano D, Stewart WF (2008) Cutaneous allodynia in the migraine population. Ann Neurol 63:148–158PubMed CentralView ArticlePubMed
  7. De Felice M, Ossipov MH, Porreca F (2011) Update on medication-overuse headache. Curr Pain Headache Rep 15(1):79–83PubMed CentralView ArticlePubMed
  8. Bellei E, Monari E, Cuoghi A, Bergamini S, Guerzoni S, Ciccarese M, Ozben T, Tomasi A, Pini LA (2013) Discovery by a proteomic approach of possible early biomarkers of drug-induced nephrotoxicity in medication-overuse headache. J Headache Pain 14:6PubMed CentralView ArticlePubMed
  9. Urade Y, Hayaishi O (2000) Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim Biophys Acta 1482:259–271View ArticlePubMed
  10. Ito S, Okuda-Ashitaka E, Minami T (2001) Central and peripheral roles of prostaglandins in pain and their interactions with novel neuropeptides nociceptin and nocistatin. Neurosci Res 41:299–332View ArticlePubMed
  11. Melegos DN, Grass L, Pierratos A, Diamandis EP (1999) Highly elevated levels of prostaglandin D synthase in the serum of patients with renal failure. Urology 53:32–37View ArticlePubMed
  12. Eguchi N, Minami T, Shirafuji N, Kanaoka Y, Tanaka T, Nagata A, Yoshida N, Urade Y, Ito S, Hayaishi O (1999) Lack of tactile pain (allodynia) in lipocalin-type prostaglandin D synthase mice. Proc Natl Acad Sci U S A 96:726–730PubMed CentralView ArticlePubMed
  13. Maesaka JK, Palaia T, Fishbane S, Ragolia L (2002) Contribution of prostaglandin D2 synthase to progression of renal failure and dialysis dementia. Semin Nephrol 22(5):407–414View ArticlePubMed
  14. Bellei E, Cuoghi A, Monari E, Bergamini S, Fantoni LI, Zappaterra M, Guerzoni S, Bazzocchi A, Tomasi A, Pini LA (2012) Proteomic analysis of urine in medication-overuse headache patients: possible relation with renal damages. J Headache Pain 13:45–52PubMed CentralView ArticlePubMed
  15. Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254View ArticlePubMed
  16. Bellei E, Rossi E, Lucchi L, Uggeri S, Albertazzi A, Tomasi A, Iannone A (2008) Proteomic analysis of early urinary biomarkers of renal changes in type 2 diabetic patients. Proteomics Clin Appl 2:478–491View ArticlePubMed
  17. Bellei E, Bergamini S, Monari E, Fantoni LI, Cuoghi A, Ozben T, Tomasi A (2011) High-abundance proteins depletion for serum proteomic analysis: concomitant removal of non-targeted proteins. Amino Acids 40:145–156View ArticlePubMed
  18. Burstein R, Yarnitsky D, Goor-Aryeh I, Ransil BJ, Bajwa ZH (2000) An association between migraine and cutaneous allodynia. Ann Neurol 47:614–624View ArticlePubMed
  19. Sandkühler J (2009) Models and mechanisms of hyperalgesia and allodynia. Physiol Rev 89:707–758View ArticlePubMed
  20. Mathew NT, Kailasam J, Seifert T (2004) Clinical recognition of allodynia in migraine. Neurology 63:848–852View ArticlePubMed
  21. Burstein R, Cutrer MF, Yarnitsky D (2000) The development of cutaneous allodynia during a migraine attack. Brain 123:1703–1709View ArticlePubMed
  22. Tietjen GE, Brandes JL, Peterlin BL, Eloff A, Dafer RM, Stein MR, Drexler E, Martin VT, Hutchinson S, Aurora SK, Recober A, Herial NA, Utley C, White L, Khuder SA (2009) Allodynia in migraine: association with comorbid pain conditions. Headache 49:1333–1344View ArticlePubMed
  23. Denk F, McMahon SB (2012) Chronic pain: emerging evidence for the involvement of epigenetics. Neuron 73:435–444PubMed CentralView ArticlePubMed
  24. Wuchty S (2014) Controllability in protein interaction networks. PNAS 111(19):7156–7160PubMed CentralView ArticlePubMed
  25. Jamieson DG, Moss A, Kennedy M, Jones S, Nenadic G, Robertson DL, Sidders B (2014) The pain interactome: connecting pain-specific protein interactions. Pain 155(11):2243–2252PubMed CentralView ArticlePubMed
  26. Urade Y, Hayaishi O (2000) Prostaglandin D synthase: structure and function. Vitam Horm 58:89–120View ArticlePubMed
  27. Zappaterra M, Guerzoni S, Cainazzo MM, Ferrari A, Pini LA (2011) Basal cutaneous pain threshold in headache patients. J Headache Pain 12:303–310PubMed CentralView ArticlePubMed
  28. Ferraro S, Grazzi L, Mandelli ML, Aquino D, Di Fiore D, Usai S, Bruzzone MG, Di Salle F, Bussone G, Chiapparini L (2012) Pain processing in medication overuse headache: a functional magnetic resonance imaging (fMRI) study. Pain Med 13:255–262View ArticlePubMed
  29. Hoffmann A, Nimtz M, Conradt HS (1997) Molecular characterization of β-trace protein in human serum and urine: a potential diagnostic marker for renal diseases. Glycobiology 7(4):499–506View ArticlePubMed
  30. Ogawa M, Hirawa N, Tsuchida T, Eguchi N, Kawabata Y, Numabe A, Negoro H, Hakamada-Taguchi R, Seiki K, Umemura S, Urade Y, Uehara Y (2006) Urinary excretions of lipocalin-type prostaglandin D2 synthase predict the development of proteinuria and renal injury on OLETF rats. Nephrol Dial Transplant 21:924–934View ArticlePubMed
  31. Lhotta K (2010) Uromodulin and chronic kidney disease. Kidney Blood Press Res 33:393–398View ArticlePubMed
  32. Zhou J, Chen Y, Liu Y, Shi S, Wang S, Li X, Zhang H, Wang H (2013) Urinary uromodulin excretion predicts progression of chronic kidney disease resulting from IgA nephropathy. PLoS ONE 8(8), e71023PubMed CentralView ArticlePubMed
  33. Rampoldi L, Scolari F, Amoroso A, Ghiggeri G, Devuyst O (2011) The rediscovery of uromodulin (Tamm-Horsfall protein): from tubulointerstitial nephropathy to chronic kidney disease. Kidney Int 80:338–347View ArticlePubMed
  34. Prajczer S, Heidenreich U, Pfaller W, Kotanko P, Lhotta K, Jennings P (2010) Evidence for a role of uromodulin in chronic kidney disease progression. Nephrol Dial Transplant 25:1896–1903View ArticlePubMed
  35. Shore N, Khurshid R, Saleem M (2010) Alpha-1-microglobulin: a marker for early detection of tubular disorders in diabetic nephropathy. J Ayub Med Coll Abbottabad 22(4):53–55PubMed
  36. Yu H, Yanagisawa Y, Forbes MA, Cooper EH, Crockson RA, MacLennan ICM (1983) Alpha-1-microglobulin: an indicator protein for renal tubular function. J Clin Pathol 36:253–259PubMed CentralView ArticlePubMed
  37. Hong CY, Hughes K, Chia KS, Ng V, Ling SL (2003) Urinary α1-microglobulin as a marker of nephropathy in type 2 diabetic asian subjects in Singapore. Diabetes Care 26:338–342View ArticlePubMed
  38. Shlipak MG, Mattes MD, Peralta CA (2013) Update on cystatin C: incorporation into clinical practice. Am J Kidney Dis 62(3):595–603PubMed CentralView ArticlePubMed
  39. Conti M, Moutereau S, Zater M, Lallali K, Durrbach A, Manivet P, Eschwege P, Loric S (2006) Urinary cystatin C as a specific marker of tubular dysfunction. Clin Chem Lab Med 44(3):288–291View ArticlePubMed
  40. Kim SS, Song SH, Kim IJ, Jeon YK, Kim BH, Kwak IS, Lee EK, Kim YK (2013) Urinary cystatin C and tubular proteinuria predict progression of diabetic nephropathy. Diabetes Care 36:656–661PubMed CentralView ArticlePubMed
  41. Westhuyzen J (2006) Cystatin C: a promising marker and predictor of impaired renal function. Ann Clin Lab Sci 36(4):387–394PubMed
  42. Feinstein AR, Heinemann LAJ, Curhan GC, Delzell E, DeSchepper PJ, Fox JM, Graf H, Luft FC, Michielsen P, Mihatsch MJ, Suissa S, van der Woude F, Willich S (2000) Relationship between nonphenacetin combined analgesics and nephropathy: a review. Kidney Int 58:2259–2264View ArticlePubMed
  43. van der Woude FJ, Heinemann LA, Graf H, Lewis M, Moehner S, Assmann A, Kühl-Habich D (2007) Analgesics use and ESRD in younger age: a case-control study. BMC Nephrol 8:15–26PubMed CentralView ArticlePubMed
  44. Zhang WY (2001) A benefit-risk assessment of caffeine as an analgesic adjuvant. Drug Saf 24(15):1127–1142View ArticlePubMed
  45. Waddington F, Naunton M, Thomas J (2015) Paracetamol and analgesic nephropathy: are you kidneying me? Int Med Case Rep J 8:1–5PubMed CentralPubMed
  46. Russell MB, Lundqvist C (2012) Prevention and management of medication overuse headache. Curr Opin Neurol 25:290–295View ArticlePubMed
  47. Lai JTF, Dereix JDC, Ganepola RP, Nightingale PG, Markey KA, Aveyard PN, Sinclair AJ (2014) Should we educate about the risks of medication overuse headache? J Headache Pain 15:10PubMed CentralView ArticlePubMed
  48. Westergaard ML, Hansen EH, Glümer C, Jensen RH (2015) Prescription pain medications and chronic headache in Denmark: implications for preventing medication overuse. Eur J Clin Pharmacol DOI: 10.1007/s00228-015-1858-3
Metadata
Title
Validation of potential candidate biomarkers of drug-induced nephrotoxicity and allodynia in medication-overuse headache
Authors
Elisa Bellei
Emanuela Monari
Stefania Bergamini
Aurora Cuoghi
Aldo Tomasi
Simona Guerzoni
Michela Ciccarese
Luigi Alberto Pini
Publication date
01-12-2015
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2015
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/s10194-015-0559-8

Other articles of this Issue 1/2015

The Journal of Headache and Pain 1/2015 Go to the issue

Book review

Book review: Advanced Headache Therapy by Lawrence Robbins

Research article

A study of cochlear and auditory pathways in patients with tension-type headache

Short report

Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study

Research article

Positive effects of the progestin desogestrel 75 μg on migraine frequency and use of acute medication are sustained over a treatment period of 180 days

Research article

Validation of the Patient Health Questionnaire-9 (PHQ-9) and PHQ-2 in patients with migraine

Research article

Masticatory sensory-motor changes after an experimental chewing test influenced by pain catastrophizing and neck-pain-related disability in patients with headache attributed to temporomandibular disorders